Table 3.
Quality assessment of studies of sedation for VCUG, including Jadad score [86].
| Authors; year; country; reference | Randomised | Randomisation described | Blinded | Allocation concealment | Withdrawals and dropouts? | Control | Placebo group | A priori power | Jadad score [86] |
|---|---|---|---|---|---|---|---|---|---|
| I. Akil, M. Ozkol, O. Y. Ikizoglu, M. Polat, O. Y. Tuncyurek, O. Taskin, H. Yuksel; 2005; Turkey [41] | Quasi | Y | Y (not described as double blind) | Cherry-flavoured liquid | N | Y | Y | N | 1 (poor) |
|
| |||||||||
| J. S. Elder, R. Longenecker; 1995; USA [43] | N | — | N | Kool-aid (artificial sweetner) | N | Y | Y | N | 0 (poor) |
|
| |||||||||
| D. W. Herd, K. A. McAnulty, N. A. Keene, D. E. Sommerville; 2006; New Zealand [45] | Y | Y | Y (blinding analysis done) | Mango and orange juices | Y | Y | Y | Y; 80% for GDRS; 90% for VUR grade | 5 (excellent)* |
|
| |||||||||
| I. Keidan, R. Zaslansky, M. Weinberg, A. Ben-Shlush, J. M. Jacobson, A. Augarten, Y. Mor; 2005; Israel [47] | Y | N | N | — | N | Y | N | N | 1 (poor) |
|
| |||||||||
| P. A. Merguerian, S. T. Corbett, J. Cravero; 2006; USA [48] | N | — | — | — | — | Y (historical) | N | N | 0 (poor) |
|
| |||||||||
| E. Stokland, S. Andréasson, B. Jacobsson, U. Jodal, B. Ljung; 2003; Sweden [52] | Y | Y | Y | Described | N | Y | Y | N | 4 (good) |
|
| |||||||||
| J. L. Zier, K. A. Kvam, S. C. Kurachek, M. Finkelstein; 2007; USA [59] | N | — | N | — | Y | Y | Y | N | 1 (poor) |
*Authors' self-score.